Mainz Biomed N.V. (QUCY) - Net Assets
Based on the latest financial reports, Mainz Biomed N.V. (QUCY) has net assets worth $641.60K USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.33 Million) and total liabilities ($4.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Mainz Biomed N.V. debt and liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $641.60K |
| % of Total Assets | 12.04% |
| Annual Growth Rate | -43.65% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 94.45 |
Mainz Biomed N.V. - Net Assets Trend (2021–2025)
This chart illustrates how Mainz Biomed N.V.'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of Mainz Biomed N.V. for the complete picture of this company's asset base.
Annual Net Assets for Mainz Biomed N.V. (2021–2025)
The table below shows the annual net assets of Mainz Biomed N.V. from 2021 to 2025. For live valuation and market cap data, see market value of Mainz Biomed N.V..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $641.60K | -89.39% |
| 2024-12-31 | $6.05 Million | +86.09% |
| 2023-12-31 | $3.25 Million | -76.95% |
| 2022-12-31 | $14.10 Million | +121.60% |
| 2021-12-31 | $6.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mainz Biomed N.V.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8825741700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $105.54 Million | 16450.12% |
| Total Equity | $641.60K | 100.00% |
Mainz Biomed N.V. Competitors by Market Cap
The table below lists competitors of Mainz Biomed N.V. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mask Investments Limited
NSE:MASKINVEST
|
$5.14 Million |
|
Willow Biosciences Inc
TO:WLLW
|
$5.15 Million |
|
YGL Convergence Bhd
KLSE:0086
|
$5.15 Million |
|
Oberstdorfer Bergbahn AG
MU:KVO
|
$5.16 Million |
|
Rayong Wire Industries Public Company Limited
BK:RWI
|
$5.14 Million |
|
Better Choice Company Inc
NYSE MKT:BTTR
|
$5.13 Million |
|
Eversafe Rubber Bhd
KLSE:0190
|
$5.13 Million |
|
Vestand Inc.
NASDAQ:VSTD
|
$5.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mainz Biomed N.V.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,046,543 to 641,600, a change of -5,404,943 (-89.4%).
- Net loss of 16,210,718 reduced equity.
- New share issuances of 8,248,261 increased equity.
- Other comprehensive income decreased equity by 27,038,075.
- Other factors increased equity by 29,595,589.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.21 Million | -2526.61% |
| Share Issuances | $8.25 Million | +1285.58% |
| Other Comprehensive Income | $-27.04 Million | -4214.16% |
| Other Changes | $29.60 Million | +4612.78% |
| Total Change | $- | -89.39% |
Book Value vs Market Value Analysis
This analysis compares Mainz Biomed N.V.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.01x to 5.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $35.29 | $0.41 | x |
| 2022-12-31 | $39.83 | $0.41 | x |
| 2023-12-31 | $8.00 | $0.41 | x |
| 2024-12-31 | $6.24 | $0.41 | x |
| 2025-12-31 | $0.07 | $0.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mainz Biomed N.V. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2526.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3018.31%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 8.30x
- Recent ROE (-2526.61%) is below the historical average (-812.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -183.77% | -2024.79% | 0.06x | 1.58x | $-12.33 Million |
| 2022 | -187.20% | -4979.90% | 0.03x | 1.44x | $-27.80 Million |
| 2023 | -809.29% | -2936.50% | 0.06x | 4.74x | $-26.62 Million |
| 2024 | -358.07% | -2421.80% | 0.07x | 2.19x | $-22.26 Million |
| 2025 | -2526.61% | -3018.31% | 0.10x | 8.30x | $-16.27 Million |
Industry Comparison
This section compares Mainz Biomed N.V.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $543,908,184
- Average return on equity (ROE) among peers: -221.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mainz Biomed N.V. (QUCY) | $641.60K | -183.77% | 7.30x | $5.14 Million |
| Agilent Technologies Inc (A) | $2.51 Billion | -1.24% | 2.04x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $11.11 Million | -144.24% | 0.30x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $9.85 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $154.44 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Mainz Biomed N.V.
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more